Shares of Abaxis Inc. (NASDAQ:ABAX) traded up 2.2% on Monday . The company traded as high as $47.94 and last traded at $47.38, with a volume of 167,070 shares traded. The stock had previously closed at $46.36.

A number of analysts have weighed in on the company. Feltl & Co. cut Abaxis from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research raised Abaxis from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. Canaccord Genuity reaffirmed a “hold” rating on shares of Abaxis in a research report on Tuesday, April 19th. TheStreet raised Abaxis from a “hold” rating to a “buy” rating in a research report on Thursday, June 9th. Finally, CL King assumed coverage on Abaxis in a research report on Friday, April 1st. They set a “neutral” rating for the company. Four research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $45.30.

The firm has a market capitalization of $1.07 billion and a price-to-earnings ratio of 34.77. The stock has a 50-day moving average price of $48.20 and a 200 day moving average price of $45.50.

Abaxis (NASDAQ:ABAX) last posted its quarterly earnings results on Thursday, July 21st. The company reported $0.30 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.32 by $0.02. The business earned $57.70 million during the quarter, compared to the consensus estimate of $58.70 million. During the same quarter in the prior year, the company earned $0.31 earnings per share. On average, analysts anticipate that Abaxis Inc. will post $1.39 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 15th. Shareholders of record on Thursday, September 1st will be paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.00%. The ex-dividend date is Tuesday, August 30th.

In other Abaxis news, Director Henk Evenhuis sold 3,000 shares of the business’s stock in a transaction on Monday, May 9th. The shares were sold at an average price of $45.00, for a total transaction of $135,000.00. Following the sale, the director now directly owns 15,400 shares of the company’s stock, valued at approximately $693,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Achim Henkel sold 5,000 shares of the business’s stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $44.43, for a total transaction of $222,150.00. Following the sale, the director now directly owns 53,609 shares in the company, valued at $2,381,847.87. The disclosure for this sale can be found here.

Other hedge funds have recently made changes to their positions in the company. WBI Investments Inc. purchased a new stake in shares of Abaxis during the fourth quarter valued at about $1,051,000. US Bancorp DE increased its stake in shares of Abaxis by 6.5% in the fourth quarter. US Bancorp DE now owns 23,142 shares of the company’s stock valued at $1,289,000 after buying an additional 1,421 shares during the period. Morgan Stanley increased its stake in shares of Abaxis by 28.2% in the fourth quarter. Morgan Stanley now owns 29,523 shares of the company’s stock valued at $1,643,000 after buying an additional 6,489 shares during the period. Deere & Co. increased its stake in shares of Abaxis by 349.9% in the fourth quarter. Deere & Co. now owns 41,045 shares of the company’s stock valued at $2,285,000 after buying an additional 31,921 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Abaxis by 1.4% in the fourth quarter. Rhumbline Advisers now owns 45,742 shares of the company’s stock valued at $2,547,000 after buying an additional 625 shares during the period.

Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.